A UK‐based cost–utility analysis of radiofrequency ablation or oesophagectomy for the management of high‐grade dysplasia in Barrett’s oesophagus

Aliment Pharmacol Ther 2010; 32: 1332–1342

[1]  N. Shaheen,et al.  A cost-utility analysis of ablative therapy for Barrett's esophagus. , 2009, Gastroenterology.

[2]  Hiroshi Mashimo,et al.  Radiofrequency ablation in Barrett's esophagus with dysplasia. , 2009, The New England journal of medicine.

[3]  Arnold Knijn,et al.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. , 2009, European journal of cancer.

[4]  David Forman,et al.  Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. , 2009, The Lancet. Oncology.

[5]  Ananya Das,et al.  Circumferential and Focal Ablation of Barrett's Esophagus Containing Dysplasia , 2009, The American Journal of Gastroenterology.

[6]  P. Fockens,et al.  Eradication of Barrett Esophagus with Early Neoplasia by Radiofrequency Ablation, with or without Endoscopic Resection , 2008, Journal of Gastrointestinal Surgery.

[7]  Kenneth J. Chang,et al.  Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. , 2008, Gastrointestinal endoscopy.

[8]  R. Hawes,et al.  M1030 Impact of Barrett's Esophagus Containing Dysplasia On Patient Quality of Life: Interim Results of a Randomized, Sham-Controlled Trial of Radiofrequency Ablation (AIM Dysplasia Trial) , 2008 .

[9]  P. Fockens,et al.  Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients , 2008, Endoscopy.

[10]  P. Fockens,et al.  Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system , 2008, Endoscopy.

[11]  H. El‐Serag,et al.  Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. , 2008, Gastrointestinal endoscopy.

[12]  P. Mcculloch,et al.  Systematic review of minimally invasive resection for gastro‐oesophageal cancer , 2007, The British journal of surgery.

[13]  J. Peters,et al.  Esophagectomy for High Grade Dysplasia is Safe, Curative, and Results in Good Alimentary Outcome , 2007, Journal of Gastrointestinal Surgery.

[14]  B. Overholt,et al.  Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. , 2007, Gastrointestinal endoscopy.

[15]  M. Aalabaf-Sabaghi.  Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[16]  D. Alderson,et al.  Health‐related quality of life among patients cured by surgery for esophageal cancer , 2007, Cancer.

[17]  Kenneth K Wang,et al.  Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. , 2007, Gastroenterology.

[18]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[19]  R. Sampliner,et al.  Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  Tasha A K Gandamihardja,et al.  Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. , 2006, Journal of the American College of Surgeons.

[21]  C. Pellegrini,et al.  Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for barrett’s esophagus , 2006, Journal of Gastrointestinal Surgery.

[22]  M. Pitt,et al.  Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. , 2006, Health technology assessment.

[23]  Michael Vieth,et al.  Prevalence of Barrett's esophagus in the general population: an endoscopic study. , 2005, Gastroenterology.

[24]  V. Sujendran,et al.  Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  Bergein F Overholt,et al.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. , 2005, Gastrointestinal endoscopy.

[26]  M. Feith,et al.  Early Esophageal Cancer: Pattern of Lymphatic Spread and Prognostic Factors for Long-Term Survival After Surgical Resection , 2005, Annals of surgery.

[27]  B. Edil,et al.  Surgical treatment of esophageal high-grade dysplasia. , 2005, The Annals of thoracic surgery.

[28]  J. Bond,et al.  A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. , 2005, Health technology assessment.

[29]  G. Sanders,et al.  Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. , 2004, Gastrointestinal endoscopy.

[30]  F Berrino,et al.  EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Masoud Panjehpour,et al.  Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. , 2003, Gastrointestinal endoscopy.

[32]  B. Overholt,et al.  What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis , 2003, Gut.

[33]  J. Goldblum,et al.  Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy? , 2003, Gut.

[34]  C. Yeo,et al.  Barrett’s esophagus with high grade dysplasia: Surgical results and long-term outcome— An update , 2003, Journal of Gastrointestinal Surgery.

[35]  P. Pairolero,et al.  High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. , 2002, The Annals of thoracic surgery.

[36]  M. Sprangers,et al.  Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences , 2002, British Journal of Cancer.

[37]  P. Moayyedi,et al.  Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. , 2002, Gastroenterology.

[38]  Dennis M. Riehle,et al.  Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. , 2001, Gastroenterology.

[39]  D. Bowrey,et al.  Barrett's esophagus: a surgical disease? , 2000, The American journal of gastroenterology.

[40]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[41]  A. Ruol,et al.  Oesophageal resection for high‐grade dysplasia in Barrett's oesophagus , 2000, The British journal of surgery.

[42]  A. Csendes,et al.  Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[43]  P. Schauer,et al.  Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. , 2000, Surgery.

[44]  J H Peters,et al.  Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. , 1999, Annals of surgery.

[45]  B. Sibbald,et al.  Understanding controlled trials: Why are randomised controlled trials important? , 1998 .

[46]  R. Jones,et al.  HEARTBURN, OESOPHAGITIS AND BARRETT'S OESOPHAGUS IN SELF‐MEDICATING PATIENTS IN GENERAL PRACTICE , 1996, The British journal of clinical practice.

[47]  H. R. Matthews,et al.  Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England , 1995, The British journal of surgery.

[48]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[49]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[50]  K. Behrns.  Endoscopic and Surgical Treatment of Mucosal (T1a) Esophageal Adenocarcinoma in Barrett's Esophagus , 2010 .

[51]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[52]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[53]  N. Nishioka,et al.  Health and Quality of Life Outcomes Quality of Life in Patients with Various Barrett's Esophagus Associated Health States , 2022 .